Pfizer breaks below $28.50
– Pfizer broke support zone
– Likely to fall to support level 27.00
Pfizer recently broke the support zone between the support level 28.50, the 38.2% Fibonacci correction of the upward impulse from the start of July and the daily up trendline from August. The level 28.50 capped the price at the start of April, turned into support after the breakout in October and stopped wave a earlier this month.
The breakout accelerated the active wave c of the ABC correction 2 from the start of November.
Given the bearish sentiment across the large-cap pharma stocks today, Pfizer can be expected to fall further toward the next support level 27.00 (target price for the completion of the active correction 2), which stopped the previous correction (2) at the start of October and stands just below the 50% Fibonacci correction. The pharmaceutical sector fell nearly 2% today as Merck’s pipeline setback and ongoing US drug-pricing scrutiny weighed on the group. Pfizer’s $2.6bn licensing deal for early-stage CAR-T programmes, announced yesterday, has done little to support the shares.
If 27.00 holds, the correction 2 is likely to end there and Pfizer can resume its uptrend toward 28.50. A daily close above 29.75 (the top of wave b) would cancel this bearish scenario.
In the near term, sellers keep control below 28.50.


